[go: up one dir, main page]

DE69123247D1 - Verfahren zur behandlung von alkoholsucht mit nalmefen - Google Patents

Verfahren zur behandlung von alkoholsucht mit nalmefen

Info

Publication number
DE69123247D1
DE69123247D1 DE69123247T DE69123247T DE69123247D1 DE 69123247 D1 DE69123247 D1 DE 69123247D1 DE 69123247 T DE69123247 T DE 69123247T DE 69123247 T DE69123247 T DE 69123247T DE 69123247 D1 DE69123247 D1 DE 69123247D1
Authority
DE
Germany
Prior art keywords
nalmefen
alcohol addiction
treating alcohol
treating
alcoholics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69123247T
Other languages
English (en)
Other versions
DE69123247T2 (de
Inventor
John Sinclair
Harry Scheinin
Risto Lammintausta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contral Clinics Oy
Original Assignee
Alko Oy AB
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Oy AB, Orion Yhtyma Oy filed Critical Alko Oy AB
Publication of DE69123247D1 publication Critical patent/DE69123247D1/de
Application granted granted Critical
Publication of DE69123247T2 publication Critical patent/DE69123247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69123247T 1990-06-04 1991-05-10 Verfahren zur behandlung von alkoholsucht mit nalmefen Expired - Lifetime DE69123247T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene
PCT/US1991/003241 WO1991018605A1 (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
DE69123247D1 true DE69123247D1 (de) 1997-01-02
DE69123247T2 DE69123247T2 (de) 1998-01-15

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69123247T Expired - Lifetime DE69123247T2 (de) 1990-06-04 1991-05-10 Verfahren zur behandlung von alkoholsucht mit nalmefen

Country Status (19)

Country Link
US (1) US5086058A (de)
EP (1) EP0531415B1 (de)
JP (1) JP3059213B2 (de)
AT (1) ATE145329T1 (de)
AU (1) AU642748B2 (de)
CA (1) CA2084519C (de)
DE (1) DE69123247T2 (de)
DK (1) DK0531415T3 (de)
ES (1) ES2097209T3 (de)
FI (1) FI925513A0 (de)
GR (1) GR3022289T3 (de)
HU (1) HU210637B (de)
IE (1) IE77333B1 (de)
LT (1) LT3893B (de)
LV (1) LV10190B (de)
NZ (1) NZ238391A (de)
RU (1) RU2090190C1 (de)
WO (1) WO1991018605A1 (de)
ZA (1) ZA914185B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
NZ505192A (en) * 1997-12-22 2003-05-30 Euro Celtique S A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
PT1041987E (pt) * 1997-12-22 2006-07-31 Euro Celtique Sa Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
OA12215A (en) 2000-02-08 2006-05-09 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
JP4736323B2 (ja) * 2001-07-13 2011-07-27 アークレイ株式会社 分析用具を備えた濃度測定装置用の穿刺要素一体装着体、および体液採取用具
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
SI1414451T1 (sl) 2001-08-06 2009-10-31 Euro Celtique Sa Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
EP1639997A1 (de) 2002-04-05 2006-03-29 Euro-Celtique S.A. Matrix für die modifizierte Freigabe von aktiven Substanzen
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
AU2003270778B2 (en) * 2002-09-20 2009-10-08 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
WO2008051902A2 (en) 2006-10-20 2008-05-02 Cpd, Llc Method of restoring the incretin effect
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
RU2495041C2 (ru) * 2008-04-24 2013-10-10 Янссен Фармацевтика Нв Диэфирные пролекарства налмефена
PT2291380E (pt) * 2008-04-24 2011-12-22 Janssen Pharmaceutica Nv Pró-fármacos nalmefeno
WO2010003963A1 (en) * 2008-07-07 2010-01-14 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
MX2016000810A (es) 2013-07-23 2016-08-05 Euro Celtique Sa Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
WO2015163486A1 (en) * 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
CN117137917A (zh) * 2016-04-22 2023-12-01 景凯生物科技股份有限公司 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
CA2084519A1 (en) 1991-12-05
US5086058A (en) 1992-02-04
ATE145329T1 (de) 1996-12-15
HU9203835D0 (en) 1993-03-29
LV10190A (lv) 1994-10-20
LV10190B (en) 1995-06-20
IE911888A1 (en) 1991-12-04
FI925513L (fi) 1992-12-04
GR3022289T3 (en) 1997-04-30
NZ238391A (en) 1997-06-24
ZA914185B (en) 1992-07-29
AU642748B2 (en) 1993-10-28
JP3059213B2 (ja) 2000-07-04
LTIP1486A (en) 1995-09-25
EP0531415A1 (de) 1993-03-17
HUT65523A (en) 1994-06-28
EP0531415B1 (de) 1996-11-20
IE77333B1 (en) 1997-12-03
JPH06506665A (ja) 1994-07-28
RU2090190C1 (ru) 1997-09-20
FI925513A0 (fi) 1992-12-04
ES2097209T3 (es) 1997-04-01
DK0531415T3 (da) 1996-12-09
DE69123247T2 (de) 1998-01-15
LT3893B (en) 1996-04-25
HU210637B (en) 1995-06-28
WO1991018605A1 (en) 1991-12-12
AU7974091A (en) 1991-12-31
CA2084519C (en) 1999-02-09

Similar Documents

Publication Publication Date Title
DE69123247D1 (de) Verfahren zur behandlung von alkoholsucht mit nalmefen
RU92016403A (ru) Способ лечения алкоголизма налмефеном
ATE244290T1 (de) Verfahren zur herstellung synthetischer dieselbrennstoff
DE59101695D1 (de) Verfahren zur Erzeugung von niederen Olefinen.
DE60134590D1 (de) Verfahren zur Herstellung von kohlensäurehaltigem Wasser
DE59702613D1 (de) Verfahren zur herstellung von dienpolymerisatlösungen in vinylaromatischen monomeren
DE69628312D1 (de) Verfahren zur herstellung von getraenkedosenblech
DE69019753D1 (de) Verfahren zur verwendung von gashilfe während des giessens von kunststoffgegenständen.
ATE198531T1 (de) Verfahren zur herstellung von schwarzem instanttee
DE3864208D1 (de) Verfahren zur herstellung von orientierten folien.
ATE316860T1 (de) Verfahren zur automatischen herstellung von brillenlinsen
DE3874857D1 (de) Verfahren zur herstellung eines mit pfropfung modifizierten alpha-olefin-copolymers.
DE69522436D1 (de) Verfahren zur herstellung von äthylalkohol
DE59004541D1 (de) Verfahren zum Vermindern des Alkoholgehaltes alkoholischer Getränke.
DE3580611D1 (de) Verfahren zur herstellung alkoholischer getraenke.
ATE126531T1 (de) Verfahren zur gewinnung von natürlich hergestelltem chymosin.
DE69703428D1 (de) Verfahren zur herstellung wässiger lösungen von tetraalkylammoniumhydroxiden
DE58905117D1 (de) Verfahren zur herstellung von 4-chlor-2,5-dimethoxyanilin.
DE59002050D1 (de) Verfahren zur herstellung von alkanolen.
FI940969L (fi) Menetelmä vedenerottuvuuden parantamiseksi mäntyöljyn valmistusprosessissa sekä menetelmä mäntyöljyn valmistamiseksi
DE69021159D1 (de) Verfahren zum immunochemischen Bestimmen von Haptenen.
DE3485297D1 (de) Verfahren zur herstellung von aluminiumberuhigtem tiefziehstahl mit geringem mangangehalt.
DE69411005D1 (de) Verfahren zur herstellung von rechtkettigen organischen aldehydverbindungen
DE59100258D1 (de) Verfahren zur abtrennung von aromaten aus kohlenwasserstoffgemischen mit beliebigem aromatengehalt.
DE59104558D1 (de) Verfahren zur herstellung von konzentrierten wässrigen lösungen von anionischen azofarbstoffen.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CONTRAL CLINICS OY, ESPOO, FI

8364 No opposition during term of opposition